Lupus erythematosus - Lupus Eritematos
☆ Nan rezilta Stiftung Warentest 2022 ki soti nan Almay, satisfaksyon konsomatè yo ak ModelDerm te sèlman yon ti kras pi ba pase ak konsiltasyon telemedsin peye.
Li parèt tankou yon eritem yon ti kras koulè wouj violèt.
Gratèl la papiyon ki tipikman parèt sou figi an.
References
Idantifye ak klasifye cutaneous lupus erythematosus (CLE) poze defi dyagnostik, distenge li ak systemic lupus erythematosus ak patisipasyon po. Dènye etid yo fè limyè sou faktè jenetik, anviwònman ak iminolojik ki kache nan CLE. Endiksyon dwòg espesyalman te parèt kòm youn nan deklannche ki pi enpòtan pou CLE. Tretman enplike terapi aktualite ak sistemik, ki gen ladan biyolojik pwomèt (belimumab, rituximab, ustekinumab, anifrolumab, BIIB059) , ak efikasite demontre nan esè klinik.
Diagnostic challenges exist in better defining cutaneous lupus erythematosus (CLE) as an independent disease distinct from systemic lupus erythematosus with cutaneous features and further classifying CLE based on clinical, histological, and laboratory features. Recent mechanistic studies revealed more genetic variations, environmental triggers, and immunologic dysfunctions that are associated with CLE. Drug induction specifically has emerged as one of the most important triggers for CLE. Treatment options include topical agents and systemic therapies, including newer biologics such as belimumab, rituximab, ustekinumab, anifrolumab, and BIIB059 that have shown good clinical efficacy in trials.
Diagnostic challenges exist in better defining cutaneous lupus erythematosus (CLE) as an independent disease distinct from systemic lupus erythematosus with cutaneous features and further classifying CLE based on clinical, histological, and laboratory features. Recent mechanistic studies revealed more genetic variations, environmental triggers, and immunologic dysfunctions that are associated with CLE. Drug induction specifically has emerged as one of the most important triggers for CLE. Treatment options include topical agents and systemic therapies, including newer biologics such as belimumab, rituximab, ustekinumab, anifrolumab, and BIIB059 that have shown good clinical efficacy in trials.
Cutaneous lupus erythematosus (CLE) kouvri divès pwoblèm po, kèk ladan yo ta ka konekte ak pwoblèm sante pi laj. Li kategorize nan diferan kalite, tankou acute CLE (ACLE) , sub-acute CLE (SCLE) , and chronic CLE (CCLE) . CCLE gen ladan discoid lupus erythematosus (DLE) , LE profundus (LEP) , chilblain cutaneous lupus, and lupus tumidus.
Cutaneous lupus erythematosus (CLE) encompasses a wide range of dermatologic manifestations, which may or may not be associated with the development of systemic disease. Cutaneous lupus is divided into several sub-types, including acute CLE (ACLE), sub-acute CLE (SCLE) and chronic CLE (CCLE). CCLE includes discoid lupus erythematosus (DLE), LE profundus (LEP), chilblain cutaneous lupus and lupus tumidus.
Cutaneous lupus erythematosus (CLE) encompasses a wide range of dermatologic manifestations, which may or may not be associated with the development of systemic disease. Cutaneous lupus is divided into several sub-types, including acute CLE (ACLE), sub-acute CLE (SCLE) and chronic CLE (CCLE). CCLE includes discoid lupus erythematosus (DLE), LE profundus (LEP), chilblain cutaneous lupus and lupus tumidus.
Lupus erythematosus se yon gwoup maladi otoiminitè ki ka afekte diferan pati nan kò a. Gen kèk kalite, tankou systemic lupus erythematosus (SLE) , afekte plizyè ògàn, pandan ke lòt, tankou cutaneous lupus erythematosus (CLE) , sitou afekte po a. Nou kategorize diferan kalite CLE ki baze sou yon melanj de siy klinik, egzamen tisi, ak tès san, men gen anpil varyasyon ant moun. Pwoblèm po souvan devlope akòz faktè tankou ekspoze a limyè solèy la, fimen, oswa sèten medikaman.
Lupus erythematosus comprises a spectrum of autoimmune diseases that may affect various organs (systemic lupus erythematosus [SLE]) or the skin only (cutaneous lupus erythematosus [CLE]). Typical combinations of clinical, histological and serological findings define clinical subtypes of CLE, yet there is high interindividual variation. Skin lesions arise in the course of triggers such as ultraviolet (UV) light exposure, smoking or drugs
Lupus erythematosus comprises a spectrum of autoimmune diseases that may affect various organs (systemic lupus erythematosus [SLE]) or the skin only (cutaneous lupus erythematosus [CLE]). Typical combinations of clinical, histological and serological findings define clinical subtypes of CLE, yet there is high interindividual variation. Skin lesions arise in the course of triggers such as ultraviolet (UV) light exposure, smoking or drugs
Kòz lupus eritematos (lupus erythematosus) pa klè. Pami marasa ki idantik, si youn afekte gen 24% chans pou lòt la ap tou. Yo kwè ke òmòn sèks fi, limyè solèy la, fimen, defisi vitamin D, ak sèten enfeksyon yo ogmante risk la.
Tretman yo ka gen ladan NSAIDs, kortikoterapi, imunosuppressants, hydroxychloroquine, ak methotrexate. Malgre ke kortikoterapi yo efikas, itilizasyon alontèm rezilta nan efè segondè.